Obesity Drugs Fuel a Market Before and After Weight Loss, as Supplements, Body Contouring and Drug Development Evolve
Authored on
Modified
Obesity drug users spend more as food intake falls and body shape changes Related spending expands from supplement purchases to treatment for sagging skin Development of products and treatments targeting post-weight-loss needs gains momentum

The boom in obesity drugs is reshaping spending across related markets, from vitamins and supplements to cosmetic procedures. As obesity medication reduces food intake, consumers are buying more supplements to fill nutritional gaps, followed by spending to manage muscle loss and sagging skin after weight loss. Demand for protein products in particular has pushed up prices for whey protein, a key ingredient, prompting manufacturers to expand production facilities. As new markets emerge around the weight-loss process and subsequent care, pharmaceutical companies are also focusing on developing drugs that target both weight reduction and muscle preservation. Clinical trials are also underway to maintain weight loss with oral drugs or extend injection intervals to ease the burden of long-term treatment.
U.S. Supplement Sales Surpass USD 74 Billion
According to Reuters on the 21st local time, the spread of obesity drugs is helping drive growth in the U.S. vitamin and supplement market. U.S. supplement sales exceeded USD 74 billion (approximately USD 75.3 billion) last year, while growth in vitamin and supplement sales accelerated from 5% in 2024 to 7% last year. A survey found that nearly half of users of glucagon-like peptide-1 (GLP-1) obesity drugs had started taking new vitamins or supplements after beginning treatment.
Spending has also increased as consumers seek a wider range of products. A survey by Nutrition Business Journal, a U.S. health food industry publication, found that probiotics, protein and fiber products were popular among GLP-1 users. This year's consumer survey by global consultancy Boston Consulting Group also found that obesity drug users' spending on protein, fiber and collagen rose about 20% compared with before treatment. The influx of new consumers, combined with additional purchases by existing users, appears to be broadening supplement companies' customer base.
Expanding sales through social media and broader product selections at retailers are also supporting supplement consumption. Supplement sales on TikTok Shop in the United States surpassed USD 1 billion (approximately USD 1.02 billion) last year, accounting for 5.4% of all online supplement sales. This reflects the establishment of a sales channel where consumers can make purchases directly within the platform after viewing product experiences and recommendations. Brick-and-mortar retailers are also expanding their offerings to meet increased demand. Major U.S. retailer Target is broadening its supplement assortment, while specialist retailer The Vitamin Shoppe recorded double-digit sales growth in fiber and creatine this year.
Spread of Obesity Drugs Drives Surge in Demand for Protein Supplements
The particularly strong growth in demand for protein supplements reflects the combination of reduced food intake from obesity drugs and the need to maintain muscle mass. Mounjaro and Wegovy reduce food intake by suppressing appetite and prolonging feelings of fullness, which can make it difficult to consume enough protein and other essential nutrients. This is why users seeking to limit muscle loss during weight reduction turn to powders and shakes that provide protein in small portions. Online health products retailer iHerb has seen an increase in searches related to “GLP-1,” along with growing interest in supplement purchases among female customers seeking to offset muscle loss associated with weight reduction. Optimum Nutrition, a flagship brand of Irish protein products company Glanbia, reportedly recorded a 25% increase in sales in the first half of this year despite raising prices twice since last November.
Rising protein demand is also pushing up prices for whey protein, a key ingredient in supplements. Whey is a byproduct of cheese production, and protein processed from it at high concentrations is used in powdered supplements and drinks. According to commodities brokerage and analytics firm StoneX, the price of whey protein concentrate with 80% protein content (WPC80) reached EUR 20,000 (approximately USD 22,846) per metric ton in June this year, up about 90% in a year. Industry officials say processing facilities producing high-protein ingredients are struggling to keep pace with demand, as purchases by obesity drug users add to growth driven by interest in healthy eating and an aging population. To expand supply, Dutch dairy company FrieslandCampina completed its acquisition of U.S. whey protein isolate producer Wisconsin Whey Protein in January this year and doubled production capacity at its plant in Borculo, the Netherlands.
Demand for Cosmetic Procedures Also Rises
Alongside nutritional supplementation, other medications are also being used to manage gastrointestinal symptoms that occur during treatment. This is because GLP-1 drugs slow the rate at which food leaves the stomach, potentially causing heartburn or acid reflux in some users. Proton pump inhibitors (PPIs), such as omeprazole, are used to ease reflux symptoms by reducing stomach acid production. A multidisciplinary expert consensus published in the international journal Journal of Clinical Medicine also presented a case recommending dietary adjustments and short-term PPI use for a patient who developed heartburn after a GLP-1 dose increase. The approach involves maintaining the drug dose until symptoms subside and then lengthening the intervals between dose increases, helping clinicians continue weight-loss treatment while managing gastrointestinal symptoms.
Demand for care accompanying obesity treatment continues after weight loss. During treatment, users manage nutritional deficiencies and gastrointestinal symptoms; after losing weight, they turn to exercise or cosmetic procedures to address loose skin and changes in body shape. In last year's member survey by the American Society of Plastic Surgeons (ASPS), 82% of responding physicians said they had received consultation requests related to GLP-1 use. Rapid weight loss has created demand to remove excess skin left on the arms, abdomen and other areas. Interest in targeted body contouring is also growing as “trophy arms,” meaning toned arms with visible muscle definition, gain attention among some affluent women in New York. Some people combine personal training with cosmetic procedures and surgery to achieve their desired arm contours.
Table 1. Obesity Drug Development Strategies and Key Clinical Results
| Drug · Developer | Development Goal · Approach | Key Clinical Results · Progress |
|---|---|---|
| Bimagrumab Eli Lilly | Limit lean mass loss during weight reduction Combine an antibody that blocks activin signaling with semaglutide | Phase 2: average weight reduction of 22.1% over 72 weeks Fat accounted for 92.8% of weight lost Lean mass, including muscle and connective tissue, largely maintained |
| Retatrutide Eli Lilly | Increase weight-loss efficacy Simultaneously target GLP-1, GIP and glucagon receptors | Phase 3 “TRIUMPH-1” 12 mg administered once weekly to adults with obesity or overweight without diabetes Average weight reduction of 28.3% over 80 weeks; 45.3% of participants lost at least 30% Based on an efficacy analysis assuming continued assigned treatment |
| Orforglipron Eli Lilly | Maintain weight after weight loss Switch from injectable drugs to an oral GLP-1 drug | Phase 3 “ATTAIN-MAINTAIN” 376 participants who had used Wegovy or Zepbound for 72 weeks Average weight gain 52 weeks after switching: 0.9 kg in the Wegovy group, 5 kg in the Zepbound group Based on the company's disclosed efficacy analysis; met the primary objectives for weight maintenance versus placebo |
| MariTide Amgen | Extend dosing intervals Target dosing once monthly or at longer intervals | Phase 2: average weight reduction of up to approximately 20% over 52 weeks in patients with obesity without diabetes Based on an analysis assuming continued treatment Phase 3 trial underway testing dosing every 8 weeks or 3 months after switching from once-weekly injections Separate extension study evaluating weight maintenance with dosing once monthly, every 8 weeks or every 3 months |
Race to Develop Next-Generation Obesity Drugs That Also Preserve Muscle
Demand to manage muscle and body shape after weight loss also aligns with the pharmaceutical industry's drug development priorities. Bimagrumab, an antibody treatment being developed by Mounjaro maker Eli Lilly, works by blocking activin signaling, which inhibits muscle growth. The aim is to combine it with appetite-regulating obesity drugs to reduce lean mass loss during weight reduction. In a Phase 2 trial combining bimagrumab with semaglutide, the active ingredient in Wegovy, average body weight fell 22.1% over 72 weeks, with fat accounting for 92.8% of the weight lost. Lean mass, including muscle and connective tissue, was largely maintained, supporting the potential of combination treatment to reduce fat while preserving muscle.
Alongside combination therapies designed to improve body composition, research into new drugs that deliver greater weight loss is also accelerating. Eli Lilly's investigational drug retatrutide is designed to act simultaneously on receptors for three hormones: GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon. It induces weight loss by jointly regulating pathways involved in appetite, blood sugar and energy metabolism. In the Phase 3 “TRIUMPH-1” trial, disclosed by the company in May, adults with obesity or overweight without diabetes who received 12 mg once weekly achieved an average weight reduction of 28.3% over 80 weeks. The efficacy analysis assumed participants continued their assigned treatment, and 45.3% of participants in that dose group lost at least 30% of their body weight.
Oral Drugs and Long-Acting Injections Diversify Maintenance Treatment
How to maintain substantial weight loss over the long term is also a major focus of clinical trials. One prominent approach is to continue treatment by switching to an oral drug after losing weight with injections. In its Phase 3 “ATTAIN-MAINTAIN” trial, Eli Lilly evaluated the weight-maintenance effects of the oral GLP-1 drug orforglipron in 376 participants who had used Wegovy or Zepbound for 72 weeks. According to an efficacy analysis released by Eli Lilly, average body weight in the group that switched from Wegovy to orforglipron increased by 0.9 kg after 52 weeks compared with the time of switching, while the group that switched from Zepbound gained 5 kg. Although both groups regained some weight, the trial met its primary objectives assessing weight maintenance versus placebo, adding evidence for maintenance treatment using oral drugs.
Development efforts are also underway to extend injection intervals so that maintenance treatment can be continued over the long term. MariTide, an obesity drug candidate from U.S. company Amgen, is being developed for dosing once monthly or at longer intervals. In Phase 2, patients with obesity without diabetes achieved an average weight reduction of up to approximately 20% over 52 weeks, based on an analysis assuming continued treatment. Building on those results, Amgen is conducting a Phase 3 trial in which patients using existing once-weekly injections switch to MariTide administered every 8 weeks or every 3 months. A separate extension study is examining weight maintenance with dosing once monthly, every 8 weeks or every 3 months.